TMCnet News

Global Postherpetic Neuralgia Pipeline Review, H2 2016 - Research and Markets
[October 28, 2016]

Global Postherpetic Neuralgia Pipeline Review, H2 2016 - Research and Markets


Research and Markets has announced the addition of the "Postherpetic Neuralgia - Pipeline Review, H2 2016" report to their offering.

Postherpetic Neuralgia pipeline therapeutics constitutes close to 23 molecules. which approximately 23 molecules are developed by Companies. The molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 4, 7, 3, 7 and 1 respectively.

Postherpetic Neuralgia Postherpetic neuralgia is a complication of shingles, which is caused by the chickenpox (herpes zoster) virus. Signs and symptoms may include pain, sensitivity to light touch, itching and numbness and weakness or paralysis. The predisposing factors include age, people with HIV and Hodgkin's lymphoma. Treatment includes anticonvulsants, antidepressants and opioid painkillers.

Postherpetic Neuralgia - Pipeline Review, H2 2016, outlays comprehensive information on the therapeutics under development for Postherpetic Neuralgia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route f administration (RoA) and molecule type. It also reviews of key players involved in therapeutic development for Postherpetic Neuralgia and features dormant and discontinued projects.



Key Topics Covered:

  1. Introduction
  2. Postherpetic Neuralgia Overview
  3. Therapeutics Development
  4. Pipeline Products for Postherpetic Neuralgia - Overview
  5. Pipeline Products for Postherpetic Neuralgia - Comparative Analysis
  6. Postherpetic Neuralgia - Therapeutics under Development by Companies
  7. Postherpetic Neuralgia - Therapeutics under Investigation by Universities/Institutes
  8. Postherpetic Neuralgia Products Glance
  9. Late Stage Products
  10. Clinical Stage Products
  11. Early Stage Products
  12. Postherpetic Neuralgia - Products under Development by Companies
  13. Postherpetic Neuralgia - Products under Investigation by Universities/Institutes
  14. Postherpetic Neuralgia - Companies Involved in Therapeutics Development
  • Aestus Therapeutics, Inc.
  • ContraVir Pharmaceuticals, Inc.
  • Daewoong Pharmaceutical Co., Ltd.
  • Daiichi Sankyo Company, Limited
  • Immune Pharmaceuticals Inc.
  • Jiangsu Hengrui Medicine Co., Ltd.
  • KPI Therapeutics, Inc.
  • Lpath, Inc.
  • Merck & Co., Inc.
  • Patagonia Pharmaceuticals, LLC
  • Pfizer Inc.
  • Phosphagenics Limited
  • Relmada Therapeutics, Inc.
  • Scilex Pharmaceuticals, Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Toray Industries, Inc.

For more information about this report visit http://www.researchandmarkets.com/research/6khjcd/postherpetic



[ Back To TMCnet.com's Homepage ]